



A Comparison and Evaluation of Loop Diuretic Frusemide Generic vs Brand Tablets

Tamilveeran T^{a++}, Karthikeyan B^{b#} and Balamurugan K. a†*

^a *Department of Pharmacy, FEAT, Annamalai University, Annamalai Nagar, Chidambaram, Tamil Nadu, 608002, India.*

^b *School of Pharmacy, Sri Balaji Vidyapeeth, SBV Campus, Pillaiyarkuppam, Pondicherry, 607402, India.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2024/v36i47509

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/115327>

Original Research Article

Received: 20/01/2024
Accepted: 26/03/2024
Published: 30/03/2024

ABSTRACT

Branded medications are the original products developed by pharmaceutical companies and generic drugs are copies of branded drugs whose patent has expired. The research work focused on comparisons and evaluations of generic VS brand of frusemide tablets. The study includes some of the specifications that should be tested in the finished products in tablets such as appearance, thickness, diameter, weight variation, hardness, friability, disintegration time, dissolution, hardness and thickness as per pharmacopoeial & non pharmacopoeial tests were performed. The generic and brand frusemide tablets quality control results showed within the range as per IP. The in vitro drug release of generic frusemide tablets was found to be 96.7 % in 45 min

⁺⁺ *M.Pharm Student;*

[#] *B.Pharm Student;*

[†] *Associate Professor;*

^{*}*Corresponding author: E-mail: placementbala@yahoo.co.in;*

and branded tablets which showed drug release 98.3% in 45 min. Hence, it can be concluded that evaluation of loop diuretic frusemide tablets generic and brand frusemide tablets showed same deviations in the quality control results as per IP.

Keywords: Frusemide; generic; brand; quality control test.

1. INTRODUCTION

Pharmaceutical companies are developing a wide range of novel therapeutic compounds to treat illnesses through the creation of both branded and generic medications [1]. "The single comprehensive active pharmaceutical ingredient is formulated by various pharmaceutical companies by different brand names" [2]. "It is found that all the pharma industries are following the Pharmacopoeial standards which are maintained by pharmaceutical regulatory authorities during the formulation of the drugs" [3].

"The generic drugs are the copy of branded drugs whose patent has expired and the branded drugs is the original product that has been developed by innovator of a pharmaceutical company" [4]. "Both products have same active ingredients, dosage form quality and performance and generic drug are manufactured by different pharmaceutical companies under different brand names and sold under different cost either lesser or cost subsidized" [5]. "Still a significant proportion of lay people, doctors and pharmacists hold negative perceptions of generic medicines, perceiving generics as less effective, less safe, inferior in quality and more likely to cause side effects compared to their branded equivalents"[6].

But all the quality control tests for the pharmaceutical formulation are tested both in generic and brand drug as per Pharmacopoeial or in-house specification as per pharmaceutical company [7]. To keep in mind the above false suspect, the current studies aim the comparison and evaluation of frusemide tablets generic and brand to throw away the blind belief of many people that branded medications have better therapeutic efficacy than the generic medications [8].

"Frusemide promotes diuresis by blocking tubular reabsorption of sodium and chloride in the proximal and distal tubules, as well as in the thick ascending loop of Henle" [9]. "This diuretic effect is achieved through the competitive inhibition of sodium-potassium-chloride co-

transporters expressed along these tubules in the nephron, preventing the transport of sodium ions from the luminal side into the basolateral side for reabsorption" [10]. "This inhibition results in increased excretion of water along with sodium, chloride, magnesium, calcium, hydrogen, and potassium ions" [11].

2. MATERIALS AND METHODS

The current research focused to analyze compared generic vs branded quality control tests for loop diuretic tablets Frusemide(40mg), a potent loop diuretic drug used in the treatment of edema of pulmonary, cardiac, hepatic renal origin and in the management of chronic hypertension. There are many brands of frusemide tablets [Lasix (Sanofi India Ltd), Fru (Ind-Swift Limited), Frusenac(Geno Pharmaceuticals Ltd) Diaqua-2 , Lo-Aqua and etc.] of different formulation manufactured and marketed, in our study one of the Frusemide tablets which has same strength of generic and brand product was selected.

2.1 Drug Profile

It is chemically 4-Chloro-2- [(furan-2-ylmethyl)amino] -5-sulfamoylbenzoic acid ($C_{12}H_{11}ClN_2O_5S$), molar mass 330.74g mol⁻¹, category is a loop diuretic, it's bioavailability 43-69% through oral. Administration routes include subcutaneous, intramuscular, intravenous, and oral. The usual dose is 40-120 mg/day[12]. Adults with edema should take 20–80 mg once daily in one dose, or two doses of the same amount divided [13].

2.2 Chemicals and Reagents

The frusemide tablet (both generic and brand) were purchased from one of the reputed pharmacy in Chidambaram, Cuddalore district, manufactured by Zentiva private Ltd for brand and Unicare India Ltd for generic tablets were selected in the research. Ingredients used was of analytical grade (AR grade) obtained from S.D Fine chemicals, Mumbai, India. Class A glasswares (Borosil Ltd., Mumbai, India) were used throughout the research work.




Fig. 1. Structure of frusemide

3. METHODOLOGY

Frusemide 40 mg uncoated tablet of both generic and brand was subjected for quality control test as per Indian pharmacopoeia 2018[14].

3.1 Evaluation Tests for Tablets

3.1.1 Tablets appearance

“20 tablets was selected and visually inspected for their external characters such as color, shape, surface texture, presence of grooves and surface defects”[15].

3.1.2 Weight variation (%)

“20 tablets from generic and brand were weighed individually used electronic weighing balance (shimadzu). Their individual weights (X_1) were measured and recorded. The average weight (X_A) of each sample was calculated and the deviation of each tablet weight from the average weight was determined” [14].

$$\% \text{ weight variation} = (X_1 - X_A) \times 100 / X_A$$

3.1.3 Thickness (mm)

10 tablets from the representative sample was taken and individual tablet thickness was measured by using digital vernier calipers (Labpro). Average value of thickness and standard deviation values was calculated [14].

3.1.4 Hardness (kg/cm²)

Tablet hardness was measured by used hardness tester (Pfizer). From generic and brand, 10 tablets was observed and recorded for the hardness and average of ten values were noted along with standard deviation [14].

3.1.5 Friability (%)

Accurately weighed 6 tablets from generic and brand were placed separately in the Roche friabilator (Erweka, Germany) in the place of the drum. Rotated the drum for 100 rotations, at 25 rpm and removed the tablets, de-dusted and reweighed the tablets. The friability were calculated as the percentage loss of weight [14]. $\% \text{ Friability} = (W_1 - W_2) \times 100 / W_1$.

Where, W_1 = Initial weight of tablets, W_2 = Final weight of tablets.

3.1.6 Disintegration time (min)

“Disintegration time is considered to be one of the essential criteria in selecting the best formulation. The study was carried out used USP type II (Erweka, Germany) dissolution apparatus (paddle type) with water buffer as the disintegration medium. The medium was maintained at $37 \pm 0.5^\circ\text{C}$ at 28-32 cycles/min. The time point at which tablet completely disintegrates was noted as disintegration time” [14].

3.1.7 In-vitro dissolution studies

The dissolution media used in this studied was pH 5.8 phosphate buffer of volume 900 mL.

[Preparation of phosphate buffer: Solution I - Dissolve 13.61 g of potassium dihydrogen phosphate in sufficient water to produce 1000 ml. Solution II - Dissolve 35.81 g of disodium hydrogen phosphate in sufficient water to produce 1000 ml. Mix 96.4 ml of solution I with 3.6 ml of solution II].

“The apparatus (USP dissolution apparatus II) was set at the speed of 50rpm. The tablets were placed in each flask of the test apparatus. The samples were drawn for every 15 min time interval till 45 min. The volume of sample drawn was 5mL. 5mL of fresh buffer solution was replaced into the beaker to maintain the dissolution medium volume. Thus collected sample was taken and diluted to 5ml with the pH 5.8 phosphate buffer and the absorbance of these solutions was measured at 271 nm using UV Spectrophotometer” [14].

3.2 Assay of Frusemide Tablet

Weighed and powdered 20 tablets and the equivalent quantity of the powder containing 0.1 g of Frusemide was weighed and mixed in 150 ml of 0.1 M sodium hydroxide (dissolving 0.4g in 100 ml water) for 10 min. Added sufficient 0.1 M sodium hydroxide to produce 250 ml and filtered using filter paper. Diluted 5 ml to 200 ml with 0.1 M sodium hydroxide and measured the absorbance of the resulting solution at the UV spectroscopy about 271 nm. Calculated the content of $C_{12}H_{11}ClN_2O_5S$ taking 580 as the specific absorbance at 271 nm [14].

3.3 Calibration Curve

3.3.1 Scanning for λ_{max}

The solutions of had a concentration of 10 μg / ml in phosphate buffer pH 5.8 was scanned in 200nm -400 nm in spectrum basic mode (Spherionics-pc based double beam spectrophotometer 2202).

3.3.2 Preparation of calibration curve

The stock solution of frusemide (100 μg / ml) were pipette out into a series of 10 ml volumetric flask and diluted with phosphate buffer pH 5.8 to get final concentration in the range of 2 – 10 μg / ml. The absorbances of the resultant solutions was measured at 271nm for pH 5.8 phosphate buffer. Freshly prepared solutions were made for the calibration curves on 3 consecutive days [16].

4. RESULTS AND DISCUSSION

4.1 Result by Pictorial Representations of Evaluation Test for Tablets

The results of our research work conducted on generic and brands of loop diuretics frusemide tablets, met the IP requirements of quality control tests within specified limits. Shape (brand-round, generic-round) & Color (brand -white, generic-white, Surface texture (brand -smooth, generic-smooth) & Convexity (brand -flat with beveled edges, generic- flat with beveled edges) presence of cracks & chips (brand -none, generic-none). The various physical parameters of tablets like weight variation (brand -2.955%, generic-3.120%), hardness (brand -6.4kg/cm², generic-6.2kg/cm²), thickness (brand -0.406%, generic- 1.014%), friability (brand -0.94%, generic-0.77%), dissolution (brand -98.3%, generic-96.7%), assay (brand -105.1%, generic-101.2%) and disintegration time (brand -1 min 25 sec, generic -1min 39 sec) are accessed were within the pharmacopoeial specifications. Drug

Table 1. Label contents

Item	Cost of tablets - For 10 tablets Rs.	Batch No.	Manufacture Date	Expiry Date	Manufacturer
Generic	10	FST1012	11/2022	10/2024	Unicare India Ltd
Brand	5	3P1454A	04/2023	03/2026	Zentiva private Limited

Table 2. Results of appearance features of the different brands of frusemide 40 mg tablets

Parameter	Generic	Brand
Shape & Color	Round & white	Round & white
Surface texture & Convexity	Smooth & flat with beveled edges	Smooth & flat with beveled edges
Presence of cracks & chips	None	None

Table 3. Results of evaluation test for tablets

Evaluation Test for Tablets								
Drug	Average weight (mg)	% weight variation	Hardness test	Thickness test	Friability	disintegration test	Dissolution rate	Assay
	Standard as per IP	<7.5%	3-10 kg/cm ²	± 5 %	<1%	30mins	Not less than 70%	90-110%
Generic	131.7	3.120	6.2	1.014	0.94	1 min39sec	96.7	101.2
Brand	165.3	2.955	6.4	0.406	0.77	1 min25sec	98.3	105.1

Table 4. Result of calibration curves data of frusemide using pH 5.8 phosphate buffer

S.no	Concentration (µg /ml)	Absorbance
1	2	0.107
2	4	0.226
3	6	0.343
4	8	0.436
5	10	0.578




Fig. 2. % of weight variation of frusemide tablets




Fig. 3. Hardness of frusemide tablets




Fig. 4. Thickness of frusemide tablets




Fig. 5. Friability of frusemide tablets




Fig. 6. Disintegration time of frusemide tablets




Fig. 7. Cost of frusemide tablets




Fig. 8. Dissolution profile for generic drug




Fig. 9. Dissolution profile of branded drug




Fig. 10. Calibration curve of frusemide drug

release of generic tablet was found to be 96.7 % in 45 min which is lesser than the branded tablets which showed drug release 98.3% in 45 min. Hence, it could be concluded that tablets were all found to have been as per pharmaceutical specifications.

5. CONCLUSION

Finally, study suggests that generic and branded (non-generic drugs) shown equal results. Hence generic form of the drug could be widely prescribed to reduce the medication cost and make the treatment economical. Cost of the generic tablet was Rs 5 per 10 tablets, whereas cost of the brand tablet was found to be Rs 10 per 10 tablets. The generic tablet was cheaper than branded tablets. So that general people can also meet the medication cost. Generics did not have to invest major amounts of time and research because FDA testing and approval of the brand drug's ingredients is already complete. Generics can get to market quicker and be sold for much cheaper than brand drugs. Generic medicine contains the same active ingredient that had undergone all clinical trials and quality testing during its patent when it was manufactured by a brand as the non-generic medicine. Therefore, these were considered safe. Further, the pharmacovigilance centers monitor the safety and side effects of medications.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Petrova E. Innovation in the pharmaceutical industry: The process of drug discovery and development. In *Innovation and Marketing in the Pharmaceutical Industry: Emerging Practices, Research, and Policies 2013* Oct 26 New York, NY: Springer New York. 2013;19-81.
2. Allen L, Ansel HC. *Ansel's pharmaceutical dosage forms and drug delivery systems*. Lippincott Williams & Wilkins; 2013.
3. Rāgo L, Santoso B. Drug regulation: history, present and future. Drug benefits and risks: *International Textbook of Clinical Pharmacology*. 2008;2:65-77.
4. Ashlesha G, Atakale M, Shinde A, Yedge V. Generic drugs vs branded drugs: view of public. *Current Trends in Pharmacy and Pharmaceutical Chemistry*. 2020;2(2):33-8.
5. Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded–generic medicines of the same manufacturer in India. *Indian Journal of Pharmacology*. 2011;43(2):131.
6. Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of

- generic medication in the general population, doctors and pharmacists: A systematic review. *BMJ Open*. 2015;5(12): e008915.
7. Khan AN, Khar RK, Udayabanu M. Pilot study of quality of diclofenac generic products using validated in-house method: Indian drug regulatory concern. *Journal of Applied Pharmaceutical Science*. 2015;5(12):147-53.7) Greene JA. *Generic: The unbranding of modern medicine*. JHU Press; 2014.
 8. Sweetman SC editors. *Martindale, 'The Complete Drug Reference*. 36th Edition. London: Pharmaceutical Press. 2009: 1292.
 9. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. *American Journal of Physiology-Renal Physiology*. 2003;284(1): F11-21.
 10. Azlan NF, Koeners MP, Zhang J. Regulatory control of the Na-Cl co-transporter NCC and its therapeutic potential for hypertension. *Acta Pharmaceutica Sinica B*. 2021;11(5):1117-28.
 11. Burton RF. Ionic regulation and water balance. *The Mollusca-Physiology*. 1983: 293-350.
 12. Sappani HK, Karthikeyan S. 4-Chloro-2-((furan-2-ylmethyl) amino)-5-sulfamoylbenzoic Acid (FSM) and N-(Isopropylcarbamoyl)-4-(m-tolylamino) Pyridine-3-sulfonamide (TSM) as Potential Inhibitors for Mild Steel Corrosion in 1 N H₂SO₄ Medium. Part I. *Industrial & Engineering Chemistry Research*. 2014;53 (9):3415-25.
 13. Brater DC, Ellison DH, Emmett M. *Causes and treatment of refractory edema in adults*. Up to date; 2022.
 14. *Indian Pharmacopoeia*. 8th edition. 2018; 299-309 & 2135-2136).
 15. Elghnimi T, Benamer W, Walli R, Beshaban M, Benashour M. Comparative in-vitro Evaluation of Some Desloratadine Tablets Marketed in Tripoli Libya. *AlQalam Journal of Medical and Applied Sciences*. 2022:556-64.
 16. *United State Pharmacopoeia 27/ National Formulary 22*. Asian Edn., United state Pharmacopoeial Convention Inc., Rockville. 2004;2622.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/115327>